With 0.22 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.05 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.6 whereas the lowest price it dropped to was $3.8801. The 52-week range on LIXT shows that it touched its highest point at $5.14 and its lowest point at $0.64 during that stretch. Beta for the stock currently stands at 0.47.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of LIXT was up-trending over the past week, with a rise of 30.50%, but this was up by 12.09% over a month. Three-month performance surged to 280.34% while six-month performance rose 242.31%. The stock gained 119.24% in the past year, while it has gained 136.70% so far this year.
Float and Shares Shorts:
At present, 4.56 million LIXT shares are outstanding with a float of 3.54 million shares on hand for trading. On 2025-08-15, short shares totaled 44364.0, which was 97.0 higher than short shares on 1752537600. In addition to Mr. Bastiaan van der Baan M.Sc. as the firm’s President, Chief Scientific Officer & Director, Mr. Robert Neal Weingarten serves as its CFO, VP & Secretary.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-06-30, LIXT reported revenue of $0.0 and operating income of -$774809.0. The EBITDA in the recently reported quarter was -$774444.0 and diluted EPS was -$0.29.
